Emyria, UWA Secure $499K Grant for MDMA Analogue Program
Released
Released
Announcement PDF
Delivering & developing new treatments for mental
health & neurological conditions
ASX Announcement | 01 Jul 2024
Emyria and UWA Awarded $499,411 Innovation Grant to Advance
Proprietary MDMA Analogue Program
HIGHLIGHTS
$499,411 grant received from the Future Health Research and Innovation Seed Fund to
advance Emyria’s MDMA analogue drug development program with the University of
Western Australia 1
Non-dilutive funds to directly support Emyria’s mission developing, applying and testing
new therapies for mental health and selected neurodegenerative diseases
Associate Prof. Matt Piggott, a leading expert on MDMA-inspired drug discovery, will direct
the medicinal chemistry and screening program 2
Initial funds to progress a world-leading program targeting the enhancement of Parkinson’s
disease treatment
Funds to facilitate international collaborations as well as support development of
UWA-Emyria’s second program focussed on potential new treatments for PTSD
Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) focused on delivering and
developing innovative treatments for mental health and select neurological conditions, is
pleased to announce a $499,411 grant award from the Future Health Research and Innovation
(FHRI) Seed Fund in partnership with the University of Western Australia (UWA).
Grant Purpose and Significance
The FHRI Seed Fund provides Western Australian innovators with non-dilutive funding to
facilitate projects with high commercial potential. This grant will advance Emyria’s novel
MDMA analogue drug discovery pipeline with UWA over the next 18 months to help validate
our drug optimisation pipeline and potentially identify a drug candidate for development
and commercialisation.
Grant funds will be allocated to key screening assays and gold-standard animal models
delivered by global collaborators, including the National Institutes of Health (NIH), to progres
towards clinical studies.
Emyria's Unique Operating Model to Deliver Impact
Emyria is dedicated to the development of new treatments for mental health, particularly to
address major unmet needs in psychological trauma, and select neurological conditions. The
Company has established a unique operating model that delivers commercially viable clinical
services and real patient impact in the short-term while fostering high potential innovation
for long-term value.
Emyria ASX Announcement | 01 Jul 2024
1
Emyria's Unique Operating Model to Deliver Impact - cont’d
Recently, the Company established itself as one of the few clinical services, globally, with the
expertise 3, 4 , bespoke facilities 5 and regulatory approvals required to evaluate
MDMA-assisted therapy for PTSD within the legal access pathways established by Australia’s
Therapeutic Goods Administration (TGA).
Since 2021, Emyria and UWA have been creating and evaluating a library of proprietary
MDMA-like compounds as part of the Company’s long-term drug discovery and
development initiatives 6, establishing Emyria as a global leader in MDMA-related
treatments.
Emyria’s MDMA-inspired Drug Discovery with UWA
Emyria’s drug discovery partnership with UWA has created a large, patented library of novel
chemical entities that are structurally similar to MDMA but designed to elicit unique clinical
and neuro-cognitive effects. These analogues have passed initial safety screens and have the
potential to become novel and patentable treatments. The two leading drug discovery
programs are:
-
The enhancement and extension of levodopa therapy for Parkinson’s disease (PD)
The development of next-generation entactogens for drug-assisted psychotherapy
Parkinson’s Disease
Parkinson’s disease, one of the world's fastest growing neurological disorders affecting 10
million adults 7, is most commonly treated with the drug levodopa. MDMA extends the
duration of levodopa treatment, and alleviates a debilitating side effect of this therapy:
uncontrolled, involuntary movements called levodopa-induced dyskinesia (LID) 8. However,
MDMA’s psychoactivity makes it unsuitable for daily use. The only existing drug to address
LID (amantadine) has very modest efficacy, and is intolerable to many patients; hence there
is a great unmet need.
A/Prof. Piggott’s research has created a number of non-psychoactive MDMA analogues, and
identified a drug lead (UWA-121) that outperforms clinical drugs in extending and enhancing
levodopa therapy in laboratory models of LID 9. UWA and Emyria have worked in partnership
to generate a large library of patented analogues of UWA-121 (structurally similar
compounds) that are being evaluated to optimise properties and identify a drug candidate
for development.
MDMA-Assisted Psychotherapy
MDMA-assisted therapy is showing great potential for the treatment of PTSD. Nevertheless,
there is interest in MDMA-like alternatives that can deliver the desirable and positive,
prosocial effects of MDMA with shorter treatment sessions and with less potential for
adverse events.
Emyria’s drug discovery program with UWA has demonstrated that structural modifications
can be achieved with MDMA that tailors interactions with key brain targets, and either
increases or decreases metabolic stability (affecting duration of action)10.
Emyria ASX Announcement | 01 Jul 2024
2
Michael Winlo, CEO: “We are thrilled to receive this substantial grant from the West
Australian Department of Health in partnership with UWA. This brings the amount of
non-dilutive funding won this year to over $500k creating a significant boost for Emyria’s
long-term innovation pipeline and, along with our MDMA-assisted therapy evaluation
program, helps reinforce our global leadership in MDMA-related treatment delivery and
development.”
Developments Ahead for Remainder of 2024:
1.
National Phase Patent Filing: Following a clear search report from the international
patent examiner 11, indicating the novelty and potential patentability of its massive
library of novel MDMA analogues, the Company has entered the National Filing phase
in key markets.
2.
Definitive Commercial Licence Negotiation with UWA: The Company has initiated
formal licensing discussions to support commercialisation and market introduction of
the analogues covered in the first patent family.
References:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
https://www.uwa.edu.au/news/article/2024/june/wa-innovators-improving-health-and-medica
l-outcomes
https://research-repository.uwa.edu.au/en/persons/matthew-piggott
See ASX release 28 February 2024.
See ASX releases 10 January 2024 and 05 April 2024
See ASX release 10 April 2024
See ASX release 05 August 2021
https://www.parkinsons.org.au/statistics/
See ASX release 01 September 2021
Johnston,T et al A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity,
enhances l-DOPA benefit in parkinsonian primates FASEB J. 26, 2154-2163 (2012)
See Company webinar, July 2023
See ASX release 10 April 2024
This release has been approved by the Board of Emyria.
For further information, investment opportunities, or more about our approach to
mental health treatment, please contact:
Managing Director
Michael Winlo
+61 (0) 8 6559 2800
mwinlo@emyria.com
Emyria ASX Announcement | 01 Jul 2024
Media Contact
Haley Chartres
+61 (0) 423 139 163
haley@hck.digital
Corporate Advisor
Sufian Ahmed
+61 (0) 412 316 162
info@62capital.com.au
3
emyria.com
Emyria Limited develops and delivers new treatments for mental health and select neurological
conditions through through an integrated model of direct clinical services and drug development:
generates
Emyria Healthcare: Evidence-based treatment for patients not finding relief from
conventional care while also helping evaluate emerging new therapies like
MDMA-assisted therapy for PTSD 1
Emyria Data: Robust and ethically-sourced Real-World Data gathered with patients
and used to improve Emyria’s unique therapy and drug development programs.
informs
Emyria’s Pipeline: New psychedelic-assisted therapies and drug treatments for mental
health and select neurological diseases.
EMYRIA’S INTERACTIVE INVESTOR HUB
Investorhub.emyria.com Interact with Emyria’s announcements and updates
by asking questions and comments, which our team can respond to where possible.
CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press
release about future expectations, plans and prospects for the Company, the Company’s
strategy, future operations, and other statements containing the words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,”
“will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute
forward-looking statements. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important factors, including: the
Company’s ability to successfully develop its product candidates and timely complete its
planned clinical programs and the Company’s ability to obtain marketing approvals for its
product candidates. In addition, the forward-looking statements included in this press
release represents the Company’s views as of the date hereof. The Company anticipates that
subsequent events and developments will cause the Company’s views to change. However,
while the Company may elect to update these forward-looking statements at some point in
the future, the Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the Company’s views
as of any date subsequent to the date hereof.
Risks associated with the use of MDMA
All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best
placed to assess the suitability of a new medication against a patient’s individual
circumstances and medical history before proceeding. Adverse effects of MDMA include
high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare
cases it can cause loss of consciousness or trigger seizures. Other side effects include
involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating
and muscle/joint stiffness. These effects of MDMA are unlikely at low doses in the treatment
regimens used in psychedelic-assisted psychotherapy while appropriately managed in a
controlled environment with direct medical supervision.
Emyria ASX Announcement | 01 Jul 2024
4
Share your feedback
Discover